Dive Brief:
- Hologic CEO Steve MacMillan will retire after the company is acquired by funds managed by Blackstone and TPG.
- The go-private deal, announced in October, values the maker of mammography machines, cervical cancer screening tests and other diagnostics tools at $18.3 billion.
- Hologic said Monday that it has received all needed regulatory approvals for the transaction and expects the acquisition to close Tuesday. Hologic plans to name its next CEO when the acquisition closes.
Dive Insight:
MacMillan, 62, has been CEO of the firm since 2013. During his time at the company, Hologic’s revenue increased by 65%, its share price more than tripled, and its workforce grew by more than 1,500 people. Hologic reported $3.26 billion in revenue in its 2025 fiscal year ending in September.
Amy Wendell, Hologic’s lead independent director, said in a statement that MacMillan “forged a dramatic turnaround shortly after joining the Company, led us through years of consistent growth, drove our unprecedented response to the COVID pandemic, and is guiding us through a successful go-private transaction.”
Prior to working for Hologic, MacMillan was CEO of Stryker, and held senior executive roles at Pharmacia and Johnson & Johnson.
With the take-private agreement by Blackstone and TPG, Hologic’s stockholders would receive $76 per share, and up to $3 per share more if the company meets certain revenue goals for its breast health business in fiscal years 2026 and 2027. Hologic will be delisted from the Nasdaq after the deal closes. The company will keep its current headquarters in Marlborough, Massachusetts.
